Clinical outcome of cadaveric renal allografts contaminated before transplantation.
This analysis was performed to define the incidence of pretransplant microbial contamination of donor kidneys, and to assess the resultant morbidity including infections requiring therapy, and graft loss. Case records of all 638 renal allograft recipients patients transplanted in our centre during the period June 1990 to October 2000 were studied. All the recipients were given a single dose of intravenous antibiotics at the time of induction of anaesthesia. A total of 775 microbiology reports on perfusion fluid, kidney swabs and ureteric tissue were retrieved. Fifty-eight of 638 (9.1%) patients were transplanted with a graft that showed preoperative contamination. 18 of these 58 patients (31%) subsequently required antibiotic treatment. Thirty of 32 patients who received kidney contaminated with skin flora had a benign course (i.e. no unexplained, no positive blood cultures or graft infection). By contrast, seven of nine recipients with grafts whose perfusion fluid yielded lactose fermenting coliforms (LFCs) required antibiotics and three of nine of them suffered graft loss as a result. Two of these patients had bacteraemia caused by LFC, and one died. Three of five patients with positive cultures due to yeast required treatment with antifungals. None of the four patients who had graft contaminated by Staphylococcus aureus became infected. One-year 49/58 (85%) of these patients survived with functioning graft. Overall 1-year patient survival was 53/55 (92%). These data suggest that contamination of renal allografts by LFCs or yeasts need to be treated preemptively before the onset of clinical manifestations. By contrast, contamination with skin contaminants does not pose a risk to the graft.
Sharma
Ajay K
AK
Sir Peter Medawar Transplant Unit, Royal Liverpool University Hospital, University of Liverpool, Liverpool, UK. aksharmatransplant@yahoo.co.uk
Smith
Godfrey
G
Smith
Darren
D
Sinha
Sanjay
S
Rustom
Rana
R
Sells
Robert A
RA
Hammad
Abdel
A
Bakran
Ali
A
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy / Q000401:mortality; D001424:Bacterial Infections / Q000188:drug therapy / Q000401:mortality; D002102:Cadaver; D006085:Graft Survival; D006801:Humans; D007668:Kidney / Q000382:microbiology*; D016030:Kidney Transplantation / Q000009:adverse effects; D009181:Mycoses / Q000188:drug therapy; D016019:Survival Analysis; D014019:Tissue Donors; D014184:Transplantation, Homologous
D000900:Anti-Bacterial Agents; D000935:Antifungal Agents